A Novel Synthetic Biology Platform for Controlling Gene Expression
(No. T4-1847)

Principal investigator
Rotem Sorek
Faculty of Biochemistry
Department of Molecular Genetics

Overview

Background and Unmet Need
A fundamental challenge of synthetic biology and its clinical applications is the capability to control gene expression. Presently, gene expression systems for research and industry have several limitations, such as a small number of available systems, inconsistent behavior among systems, lack of sufficient dynamic range of expression, and the requirement for high concentrations of a signaling molecule to induce/repress a gene. Consequently, there is a strong need for a better and diverse array of gene expression systems.

The Solution
The team of Prof. Sorek at the Weizmann Institute of Science (WIS) has made the paradigm-shifting discovery that bacteriophages have a quorum sensing system, similar to that found in bacteria. The novel system, named Arbitrium by the Sorek team, communicates to said phages residing within bacteria, whether a lytic or lysogenic cycle is to be entered. Arbitrium system can be harnessed to a wide range of synthetic-biology and biotechnological applications.

Technology Essence
Phages can infect bacteria either in a lytic cycle, which lyses the bacterial wall, or in a lysogenic cycle in which the phage genome integrates into the bacterial genome. The research team of Prof. Sorek discovered the novel Arbitrium communication system that enables lytic or lysogenic cycle (Fig. A). The Arbitrium system functions on the basis of three genes, aimR, aimP, and aimX. AimR is a dimeric receptor that binds and activates the transcription of gene aimX, whereby AimX inhibits lysogeny leading to lysis (Fig. B). AimP is a six amino acid pro-peptide (arbitrium peptide) that is expressed following infection, secreted extracellularly, and post-translationally modified. After the arbitrium peptide accumulates to a specific concentration, the arbitrium peptide is internalized and bound by the AimR receptor, which inhibits the expression of AimX and leads to lysogeny (Fig. C). The Sorek team further determined that when infected bacteria are incubated with the arbitrium peptide from the same phage that infected them, the bacterial growth curve changes due to a shift to a lysogenic cycle (Fig. D). However, when incubated with an arbitrium peptide from a different phage, the bacterial growth curve does not shift, regardless of peptide concentration (Fig. E).

Applications and Advantages
Yeda Research & Development Co. Ltd, 95 Rehovot 7610002, Israel Tel. +972.8.9470617
- Unique system: Effectively induces or shuts off expression of a gene.
- Standard Chemistry: Uses regular six amino acid peptides, therefore standard synthesis can be used.
- Wide Dynamic Range
- Over 100 Different Systems
- Uniformity Among Systems

References


Patent Status

USA Granted: 11,542,508